PLAU antibody (AA 136-166)
Quick Overview for PLAU antibody (AA 136-166) (ABIN5531939)
Target
See all PLAU AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 136-166
-
Purification
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
-
Immunogen
- This PLAUR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 136-166 amino acids from the Central region of human PLAUR.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
For IHC-P starting dilution is: 1:50~100
For WB starting dilution is: 1:1000 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 2 mg/mL
-
Buffer
- Supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- PLAU (Plasminogen Activator, Urokinase (PLAU))
-
Alternative Name
- PLAU
-
Background
- The urokinase-type plasminogen activator receptor is a key molecule in the regulation of cell-surface plasminogen activation and plays an important role in many normal as well as pathologic processes. The human PLAUR cDNA encodes 335 amino acids including a predicted signal peptide of 22 residues and a hydrophobic C-terminal portion.1 It produces a highly glycosylated protein of about 50 kD in monocytes where it is anchored to the plasma membrane by glycosyl-phosphatidylinositol linkage. PLAUR, also known as UPAR, is directly associated with the carbohydrate-binding domain of SELL in the membrane of neutrophils, an association analogous to that between PLAUR and beta-2 integrins.2 PLAUR-mediated calcium mobilization is SELL dependent. UPAR mRNA levels correlate with the invasive potential of endometrial carcinomas and show a 33-fold increase in UPAR mRNA levels in advanced clinical stage endometrial tumors compared with normal endometrial tissue.3 Furthermore, the increase in UPAR mRNA levels correlated linearly with the progression of disease stage. UPAR protein expressioin correlated positively with rate of recurrence and mortality in patients with endometrial cancer.4 UPAR appears to be a useful prognostic marker for advanced endometrial cancer.
-
Molecular Weight
- 37 kDa
-
Gene ID
- 5329
-
UniProt
- Q03405
-
Pathways
- Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Autophagy, Smooth Muscle Cell Migration
Target
-